Limits...
Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.

Fujiwara M, Isohashi F, Mabuchi S, Yoshioka Y, Seo Y, Suzuki O, Sumida I, Hayashi K, Kimura T, Ogawa K - J. Radiat. Res. (2014)

Bottom Line: Regarding adverse effects, 24 patients (46%) had acute Grade 3-4 leukopenia and 5 (10%) had late Grade 3 gastrointestinal toxicities.No patient experienced renal toxicity.Histologic type, maximum tumor diameter, and pretreatment hemoglobin level were statistically significant prognostic factors for PFS.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 5650871, Japan fujiwara@radonc.med.osaka-u.ac.jp.

Show MeSH

Related in: MedlinePlus

(a) Overall survival, (b) progression-free survival, and (c) local control of cervical cancer by treatment modality. Kaplan–Meier estimates of overall survival, progression-free survival, and local control in 52 patients with cervical cancer treated with nedaplatin-based concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy. Dashed lines represent 95% confidence intervals.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4380049&req=5

RRU101F1: (a) Overall survival, (b) progression-free survival, and (c) local control of cervical cancer by treatment modality. Kaplan–Meier estimates of overall survival, progression-free survival, and local control in 52 patients with cervical cancer treated with nedaplatin-based concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy. Dashed lines represent 95% confidence intervals.

Mentions: Three months after completion of CCRT, 44 patients (85%) achieved CR within the pelvic lesion and 8 (15%) exhibited a partial response (PR). CR of the primary tumor was achieved by 46 patients (88%), but nine developed local recurrence. Of the 52 patients, 20 experienced treatment failure: 15 (29%) had locoregional failure, and 5 (10%) experienced only distant metastases. The estimated 5-year OS, PFS and LC rates were 78% [95% confidence interval (CI), 69–91%], 57% (95% CI, 42–70%) and 73% (95% CI, 58–84%), respectively (Fig. 1).Fig. 1.


Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.

Fujiwara M, Isohashi F, Mabuchi S, Yoshioka Y, Seo Y, Suzuki O, Sumida I, Hayashi K, Kimura T, Ogawa K - J. Radiat. Res. (2014)

(a) Overall survival, (b) progression-free survival, and (c) local control of cervical cancer by treatment modality. Kaplan–Meier estimates of overall survival, progression-free survival, and local control in 52 patients with cervical cancer treated with nedaplatin-based concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy. Dashed lines represent 95% confidence intervals.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4380049&req=5

RRU101F1: (a) Overall survival, (b) progression-free survival, and (c) local control of cervical cancer by treatment modality. Kaplan–Meier estimates of overall survival, progression-free survival, and local control in 52 patients with cervical cancer treated with nedaplatin-based concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy. Dashed lines represent 95% confidence intervals.
Mentions: Three months after completion of CCRT, 44 patients (85%) achieved CR within the pelvic lesion and 8 (15%) exhibited a partial response (PR). CR of the primary tumor was achieved by 46 patients (88%), but nine developed local recurrence. Of the 52 patients, 20 experienced treatment failure: 15 (29%) had locoregional failure, and 5 (10%) experienced only distant metastases. The estimated 5-year OS, PFS and LC rates were 78% [95% confidence interval (CI), 69–91%], 57% (95% CI, 42–70%) and 73% (95% CI, 58–84%), respectively (Fig. 1).Fig. 1.

Bottom Line: Regarding adverse effects, 24 patients (46%) had acute Grade 3-4 leukopenia and 5 (10%) had late Grade 3 gastrointestinal toxicities.No patient experienced renal toxicity.Histologic type, maximum tumor diameter, and pretreatment hemoglobin level were statistically significant prognostic factors for PFS.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 5650871, Japan fujiwara@radonc.med.osaka-u.ac.jp.

Show MeSH
Related in: MedlinePlus